Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Sponsor: Incyte Corporation
A PHASE3 clinical study on Non-segmental Vitiligo, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 15 data snapshots since 2019. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Feb 2022 — Apr 2022 [monthly]
Completed PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Completed PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .